A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis
Authors
Keywords
-
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-20
DOI
10.1186/s12885-019-6294-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).
- (2018) Yasuhide Yamada et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice
- (2017) Maria Maddalena Laterza et al. MEDICAL ONCOLOGY
- Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell'Italia Meridionale.
- (2017) E. Maiello et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)
- (2016) Gastric Cancer
- The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis
- (2016) Emil ter Veer et al. JNCI-Journal of the National Cancer Institute
- Gastric cancer
- (2016) Eric Van Cutsem et al. LANCET
- The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis
- (2016) Emil ter Veer et al. JNCI-Journal of the National Cancer Institute
- Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
- (2015) N. Haj Mohammad et al. CANCER AND METASTASIS REVIEWS
- Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
- (2015) Jinwan Wang et al. Gastric Cancer
- Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
- (2013) Richard Kim et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Management of gastric cancer in Asia: resource-stratified guidelines
- (2013) Lin Shen et al. LANCET ONCOLOGY
- Gastric cancer—molecular and clinical dimensions
- (2013) Roopma Wadhwa et al. Nature Reviews Clinical Oncology
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
- (2012) Salah-Eddin Al-Batran et al. EUROPEAN JOURNAL OF CANCER
- Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
- (2012) Chiun Hsu et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
- (2011) Xiao-Dong Li WORLD JOURNAL OF GASTROENTEROLOGY
- A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
- (2010) Jina Yun et al. EUROPEAN JOURNAL OF CANCER
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started